| INTRODUC TI ON
According to current clinical guidelines, treatment options for pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with coronary artery disease (CAD) are limited to amiodarone and vernakalant. 1 Despite commonly known drawbacks, mainly long time to conversion, amiodarone seems to be the drug of choice in general population of patients with AF with less reallife information on CAD patients available in published literature. 2, 3 Vernakalant is a fast-acting option although with a lower class of indication. 1, 4 Antazoline is a I generation antihistaminic drug with antifibrillatory properties. 5 Basic studies have suggested a multichannel mode of action resulting in, among others, changes in inter-and intraatrial conduction and prolongation of QRS and QT intervals without significant influence on atrio-ventricular node or accessory pathway effective refractory periods. [6] [7] [8] [9] In human healthy volunteers, the terminal elimination half-life of antazoline was 2.29 hours with a mean residence time 3.45 hours. 7 In the same experiment, the antazoline administration resulted in a significant decrease in stroke volume-94.9 ± 21.8 vs 82.4 ± 19.6 mL (P < 0.05). Clinically, antazoline had been administered intravenously in doses of 50-100 mg every 3-5 minutes until CV was successful or up to a cumulative dose of 250-350 mg with the efficacy as high as 70%-80% and time to conversion to sinus rhythm ranging between 7 and 20 minutes. [10] [11] [12] [13] [14] Those findings were later confirmed in the randomized controlled trial. 15 Data on antazoline administration in patients with CAD have been sparse. 10, 12, 14 In more historical studies, antazoline was administered in a wide range of CAD patients including boluses in an acute myocardial infarction (MI) in the cardiac intensive care unit. 12, 14 In the single randomized trial, 36% (n = 13) patients in the antazoline arm had a documented CAD, but a history of myocardial infarction was considered an exclusion criterion. The study was conducted mostly in the emergency department (ED). 15 In a recent publication concerning exclusively patients cardioverted in ED, over 40% of patients who were administered antazoline had a documented CAD, including a history of MI.
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The aim of the study was to assess clinical effectiveness and safety of antazoline-based therapy in patients with a stable coronary artery disease undergoing pharmacological cardioversion of shortduration atrial fibrillation in the emergency department.
| ME THODS
This was a retrospective case-control study. We searched medical records of the emergency department of a tertiary care cardiological center covering the years 2008-2012 for all patients presented with short-duration AF and who had undergone pharmacological CV.
Data on patients' general characteristics, drugs used, and the outcomes of the treatment were collected anonymously. AF history was defined as a history of AF diagnosis established before the ED visit. antazoline was the drug of choice for pharmacological CV in our center. 12 Propafenone has lower effectiveness and is contraindicated in many cases, and amiodarone has a relatively slow onset of action while flecainide and procainamide are not available in Poland. 10, 16 Due to economical restraints (lump-sum instead of fee-for-service coverage of ED patients), electrical CV is rather performed in hospitalized patients. The background antiarrhythmic therapy was not discontinued and did not affect the decision and timing of CV in the ED.
Antazoline was administered intravenously under continuous cardiac monitoring in divided doses of 50 mg every 3-5 minutes up to a maximum dose of 250-300 mg or a conversion to sinus rhythm. 10, 12, 15 Additional intravenous treatment: metoprolol in doses 2.5-5 mg for rapid ventricular response (baseline ventricular rate >140-150/min), saline, potassium, and magnesium were administered at the discretion of the ED physician.
All patients with attempted pharmacological cardioversion using intravenous antazoline were included in this analysis. The study group comprised patients with CAD, and those without CAD were considered the control group. An additional analysis was conducted for patients with CAD and a history of myocardial infarction. The analyzed outcomes included successful CV to sinus rhythm (SR) documented in ECG, hospitalization, discharge, reason for hospitalization, and serious adverse events.
The analysis was approved by the local Bioethics Committee.
| Statistical analysis
For the comparison of continuous variables between the two groups, Student's t test was used for normally distributed data (normality of distribution of all continuous variables was explored by examined skewness), and the results are presented as a mean and standard
deviation (SD). The comparison of categorical variables between
the two groups was assessed by the chi-square test, or in cases of a minimum expected count of <5, the Fisher exact test, and these are reported as the absolute numbers and percentages. Relative risk was calculated with 95% CI.
All of the hypotheses were two-tailed with a 0.05 type I error.
The statistical software package SAS 9.2 (SAS Institute Inc, Cary, NC, USA) was used for the analysis.
| RE SULTS
Considering 548 pharmacological cardioversions between 2008 and 2012, at least one dose of antazoline was administered 334 times:
138 times in CAD and 196 in the control group. The baseline characteristics of the study subjects have been summarized in Table 1 .
Patients in the CAD group were older and had more comorbidities than controls. In the CAD group, 47 (34%) had at least one previous percutaneous coronary intervention (PCI), 53 (38.4%) had a history of coronary artery bypass grafting (CABG), and 65 (47%) suffered from myocardial infarction (MI). The chronic antiarrhythmic therapy was comparable between the groups and consisted of propafenone (9.6%), amiodarone (4.2%), or sotalol (4.5%). Two patients in the CAD group had an implantable cardioverter-defibrillator (ICD), and one patient in the control group had a cardiac resynchronization therapy device.
A medium dose of antazoline was 152 ± 72 mg vs 164 ± 79 mg, P = 0.1636, in the study and control groups, respectively. Only in 19.6% of cases in the study and in 26.5% in the control group (P = 0.1402) was antazoline administered as a stand-alone drug.
Additional medications comprised iv betablockers and/or iv propafenone and were evenly distributed between study groups (Table 2) . Patients also received potassium and magnesium solutions:
83 (42.3%) vs 56 (40.6%), P = 0.8337, and 90 (45.9%) vs 66 (47.8%), P = 0.8160, in the control and CAD groups, respectively.
The safety and effectiveness of antazoline-based cardioversion of short-duration AF in patients with a stable coronary artery disease have been presented in Table 3 . In CAD patients, eight out of 138 (6%) visits concluded with a discharge despite unsuccessful CV.
Among 13 (9.5%) hospitalizations due to AF resistant to pharmacological CV, there were 11 electrical and two spontaneous CVs. A subanalysis of patients with CAD and a history of MI has been presented in Table 4 . There were no reports of pathological QTc period prolongation or complex ventricular arrhythmia occurrence.
| D ISCUSS I ON
We conducted a retrospective analysis of effectiveness and safety of antazoline-based pharmacological cardioversion of short-duration AF in patients with a stable coronary artery disease. Not surprisingly, the CAD group was older and had more comorbidities than the control group (Table 1 ). In about 70% of cases, antazoline was administered together with a small dose of betablocker, which had been a common practice described before. [10] [11] [12] In comparison with patients without CAD, in the study group, the effectiveness of antazoline was higher and the risk of adverse events resulting in hospital admission was low and comparable between groups (Table 3 ).
There was no evident explanation for higher effectiveness in CAD patients, especially that the utilized concomitant medications were similar ( Table 2 ). Possible differences in chronic pharmacotherapy between the groups might have been the cause, but that information had not been reliably noted in medical records. This was highlighted in the Limitations section of the manuscript. Little is known about the influence of chronic medication on antazoline effectiveness. In the AnPAF randomized trial, the only study with detailed information on chronic treatment, groups were balanced in terms of antiarrhythmic drugs or other medications. 15 Due to high effectiveness and relatively low number of participants in the antazoline arm, the analysis of potential influence of concomitant drugs was abandoned.
Probably, a future registry would be helpful to answer this question. The reported effectiveness of intravenous antazoline varied between studies reaching 72.2% in the randomized controlled trial, 71.6% in unselected series of patients in the emergency department, and even 83.6% in patients undergoing catheter ablation of paroxysmal atrial fibrillation. 10, 11, 15 In this study, antazoline showed a good safety profile with only 2 (1.4%) cases of adverse effects in the CAD patients leading to hospital admission. They were chest discomfort in a patient with non-ST elevation MI 4 weeks prior to the cardioversion and symptomatic sick sinus syndrome with bradycardia. Other adverse effects observed in the control group were lone cases of dizziness, nausea, chest discomfort or clinical suspicion of CAD, and episodes of atrial flutter/tachycardia after cardioversion. Observed adverse events were concordant with published reports. 10, 11, 15 In the AnPAF trial, mild adverse effects of antazoline (hot flush,
TA B L E 1 Baseline characteristics of the study participants

CAD (−) CAD (+) P
Age (mean) 66.9 ± 9.9 71.3 ± 9.1
<0.0001
Gender ( Antazoline-based therapy was also used in the group of patients with a history of myocardial infarction, where both the effectiveness and safety were similar to other patients with CAD (Table 4) . It was not unusual as in the previous report the drug was utilized even in an acute myocardial infarction, although in the intensive care setting. 12 In this series, antazoline was administered in the emergency department and almost 90% of patients were discharged after the treatment. One patient was admitted as described above.
What was surprising, 9.6% of CAD patients were administered propafenone orally on daily basis and another 9.3% were treated with iv propafenone in the ED. Class Ic antiarrhythmic drugs should generally be avoided in patients with underlying heart disease involving abnormal LV function or ischemia. 1 The reason behind this finding is unclear. A clinically reasonable explanation would be contraindication to other antiarrhythmic drugs or adverse events of such treatment in otherwise stable CAD patients. While disturbing, serious divergence from clinical guidelines in AF pharmacotherapy had been described before. 17, 18 In an American analysis published in 2013, among patients with CAD 16% and 15% of drugs used were propafenone and flecainide, respectively. 17 According to an international survey RealiseAF, CAD patients comprised 17.8% class Ic drug users in Europe, 20.8% in Asia, and 10.7% in Africa. 18 Both studies are reflection of real-life clinical practice and show that insufficient adherence to clinical guidelines is universal across the globe.
There are no studies comparing antazoline to other antiarrhythmic drugs save propafenone. 10 Due to its high effectiveness and rapid onset of action, antazoline has similar indications as vernakalant and procainamide. Vernakalant is virtually nonexistent in Poland due to its horrendously high cost exceeding the entire cost of hospitalization for electrical CV of AF and procainamide has no marketing authorization 
| Limitations
This was a retrospective case-control study, and all limitations of this methodology apply to the study.
First and most important limitation of the study was the fact that only patients deemed fit by a physician on site were administered antazoline and therefore included in the analysis. Those patients had no signs or symptoms suggesting aggravated or unstable CAD, and hence, the outcomes of the study are not generalizable for the whole population of patients with CAD. Also, the study was performed in a center with a vast experience with antazoline, which might have influenced the decision on the drug used for pharmacological cardioversion, especially in controversial situations (eg, patients with MI). 10, 12 In order to limit this bias, we included all patients who received at least one dose of antazoline regardless of any co-medications or conditions.
The second important limitation was relative scarcity of clinically important information about patients undergoing CV: a detailed history of AF treatment (including antiarrhythmic medications and anticoagulants), results of echocardiography, CHA 2 DS 2 -VASc scores, and time spent in ED were not systematically noted in medical records. A more detailed data were available only for patients referred to the ward as they either suffered from adverse effects of the treatment or were scheduled for electrical CV.
Due to the nature of source, data information on time to conversion or mild side effects not resulting in admission was unavailable.
This kind of information was meticulously described in the previously published ANPAF trial. 15 The choice of treatment, its dose regimen, and the use of concomitant drugs did not strictly follow the guidelines; however, this was a real-world data analysis which represented the clinical practice. This is consistent with the previously published data which suggested a high variation in antiarrhythmic drug use with nonguideline treatment frequently used in paroxysmal and persistent AF.
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| CON CLUS IONS
In selected patients with a stable coronary artery disease, even with a history of myocardial infarction, antazoline-based pharmacological cardioversion of short-duration atrial fibrillation may be an effective and safe therapeutic option.
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